The Takeda license revenue is non-recurring; the core operating loss (R&D + G&A of $27.2M) continues. Monitor the Phase 2 rinvatercept data expected in H1 2027 and the cash burn rate to assess the need for future capital raises.
Drugs in focus
KROS drug pipeline →rinvatercept
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- Unknown — the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
- Next catalyst
- None dated
What to watchWatch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $9.36entry
- T+1 · 8d ago −2.03%α −4.40% · $9.17
- T+5 · 4d ago +10.04%α +7.45% · $10.30
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Keros Therapeutics reported Q3 2026 net income of $14.2 million, a significant swing from a net loss of $7.3 million in Q3 2025, driven by $40 million in license revenue from Takeda.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue of $40.0M vs $14.3M in Q3 2025, driven by $40M in license revenue from Takeda
- GAAP net income of $14.2M vs net loss of $7.3M in Q3 2025
- Cash and cash equivalents of $259.5M as of Sep 30, 2026, down from $287.4M at Dec 31, 2025
- Cash runway expected into the second half of 2028
- First patient dosed in Phase 2 trial of rinvatercept for Duchenne muscular dystrophy in September 2026
- Nominated KER-206, a nonclinical ligand trap for bone remodeling, for further investigation
Financial Impact
Q3 revenue of $40.0M, GAAP net income of $14.2M, cash burn of ~$28M in the quarter
Risk Factors
- Revenue is entirely dependent on the Takeda license agreement and is not recurring
- Clinical-stage biopharma with no approved products and ongoing operating losses
- Cash runway only into H2 2028; may require additional financing before then
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000065 |
| Document: kros-20261105.htm | 0001664710-26-000065 |
| Document: 0001664710-26-000065-index-headers.html | 0001664710-26-000065 |
| Document: 0001664710-26-000065-index.html | 0001664710-26-000065 |
| Document: 0001664710-26-000065.txt | 0001664710-26-000065 |
| 8-K Data (Synthetic) | 0001664710-26-000065 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers